Jun 02, 2018
The 2018 ASCO Annual Meeting, wrapping up tomorrow in Chicago, brings together more than 32,000 oncology professionals from around the world to present and discuss the latest research in cancer treatment and patient care.
Today’s key research highlights include treatment changes for longer survival in pancreatic cancer and colorectal cancer.
Heated Abdominal Chemotherapy Not Beneficial in Patients With Advanced Colorectal Cancer (Abstract LBA350)
A randomized phase III clinical trial shows that people with advanced colorectal cancer may not need a frequently considered component of treatment – heated chemotherapy delivered to the abdomen during surgery.
Chemotherapy Regimen Extends Life by Nearly Twenty Months for People With Pancreatic Cancer (Abstract LBA400)
In a randomized phase III trial people with surgically removed pancreatic cancer who received mFOLFIRINOX, a chemotherapy regimen containing four different medicines, lived a median of 20 months longer and were cancer-free nine months longer than those who received the current standard of care, gemcitabine (Gemzar®).
Pre-Operative Chemotherapy With Radiation May Help People With Pancreatic Cancer Live Longer (Abstract LBA4002)
A randomized, phase III trial found that people who received chemotherapy with radiation (chemoradiotherapy) before pancreatic cancer surgery had better disease-free survival than those who started their treatment with surgery, which is the current standard of care.
For more information about ASCO and the 2018 ASCO Annual Meeting, visit am.asco.org.